XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.1
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Total
Cumulative Effect, Period of Adoption, Adjustment
Common Stock
Additional Paid-In Capital
Additional Paid-In Capital
Cumulative Effect, Period of Adoption, Adjustment
Accumulated Other Comprehensive Loss
Accumulated Deficit
Accumulated Deficit
Cumulative Effect, Period of Adoption, Adjustment
Beginning balance (in shares) at Dec. 31, 2020     129,344,000          
Beginning balance at Dec. 31, 2020 $ 609,635 $ (378,138) $ 129 $ 1,030,577 $ (465,006) $ 1,530 $ (422,601) $ 86,868
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Issuance of common stock in connection with equity offering, net of offering costs (in shares)     10,975,000          
Issuance of common stock in connection with equity offering, net of offering costs 1,091,466   $ 11 1,091,455        
Equity component on conversions of 2023 notes and 2025 notes (11,305)     (11,305)        
Issuance of common stock upon conversions of 2023 notes (in shares)     126,000          
Issuance of common stock upon conversions of 2023 notes 11,237     11,237        
Net proceeds from capped call related to conversions of 2023 notes and 2025 notes 23,577     23,577        
Issuance of common stock upon exercise of stock options (in shares)     44,000          
Issuance of common stock upon exercise of stock options 346     346        
Net share settlement of equity awards (in shares)     828,000          
Net share settlement of equity awards (59,175)   $ 1 (59,176)        
Share-based compensation expense 23,647     23,647        
Other comprehensive loss (2,768)         (2,768)    
Net income (loss) (65,179)           (65,179)  
Ending balance (in shares) at Mar. 31, 2021     141,317,000          
Ending balance at Mar. 31, 2021 $ 1,243,343   $ 141 1,645,352   (1,238) (400,912)  
Beginning balance (in shares) at Dec. 31, 2021 136,951,956   136,952,000          
Beginning balance at Dec. 31, 2021 $ 1,106,917   $ 137 1,449,305   (5,334) (337,191)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Repurchases of common stock (in shares)     (10,725,000)          
Repurchases of common stock (300,450)   $ (11) (300,439)        
Issuance of common stock upon exercise of stock options (in shares)     54,000          
Issuance of common stock upon exercise of stock options 455     455        
Net share settlement of equity awards (in shares)     401,000          
Net share settlement of equity awards (7,466)   $ 1 (7,467)        
Share-based compensation expense 34,911     34,911        
Other comprehensive loss (31,588)         (31,588)    
Net income (loss) $ 5,742           5,742  
Ending balance (in shares) at Mar. 31, 2022 126,681,972   126,682,000          
Ending balance at Mar. 31, 2022 $ 808,521   $ 127 $ 1,176,765   $ (36,922) $ (331,449)